ERBB2 and cancer: Hereby, molecular subtyping provides decision support on whether and what systemic therapy should be appropriate, such as endocrine therapy in luminal cancers, targeted therapy in human epidermal growth factor receptor 2 (HER2)-positive cancers, or immune therapy in triple negative cancers [13, 27].